<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01622660</url>
  </required_header>
  <id_info>
    <org_study_id>11-191</org_study_id>
    <nct_id>NCT01622660</nct_id>
  </id_info>
  <brief_title>Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy</brief_title>
  <official_title>Phase II Study of Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      Gemcitabine and Cisplatin are standard chemotherapy drugs used to treat advanced urothelial&#xD;
      cancer. There is no standard chemotherapy for patients who cannot receive Cisplatin. However,&#xD;
      most patients are treated with the chemotherapy drugs Gemcitabine and Carboplatin.&#xD;
&#xD;
      In this study, the researchers hope to learn what effects, good and/or bad, the combination&#xD;
      of Gemcitabine and Pazopanib has on urothelial cancer. Gemcitabine is given intravenously&#xD;
      (through the veins) and works by killing rapidly dividing cells in the body, including cancer&#xD;
      cells. Pazopanib is an oral chemotherapy and works by decreasing the blood supply to tumors&#xD;
      which limits the tumor's source of oxygen and nutrients.&#xD;
&#xD;
      The combination of Gemcitabine and Pazopanib is being tested in research studies such as this&#xD;
      one. As of August 2011, more than 18 patients with various types of cancer have received&#xD;
      treatment with Gemcitabine and Pazopanib. The main goal of this clinical research study is to&#xD;
      learn if the study drugs Gemcitabine and Pazopanib can shrink or slow the growth of&#xD;
      urothelial cancer. The safety of this drug will also be studied. The physical state, changes&#xD;
      in the size of the tumor, and laboratory findings will help us decide if the combination of&#xD;
      Gemcitabine and Pazopanib is safe and effective.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Safety reasons&#xD;
  </why_stopped>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>2 years</time_frame>
    <description>Progression Free Survival will be calculated from the start of treatment until progressive disease or death. Patients who die before documented progression will be considered failures at their time of death. If the patient did not progress or die, the patient will be censored on the date of last follow-up. Response and progression will be evaluated in this study using the international criteria by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 Measurable lesions: lesions that can be accurately measured in at least one dimension with longest diameter ≥ 10 mm by clinical exam or with spiral CT scan or MRI (no less than double the slice thickness and a minimum of 10mm). Malignant lymph nodes must be 15 mm in the short axis when assessed by spiral CT scan to be considered measurable. Non-measurable lesions: all other lesions (or sites of disease) including small lesions (longest diameter &lt; 20 mm with conventional techniques or &lt; 10 mm u</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Gemcitabine and Pazopanib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a phase II trial of gemcitabine and pazopanib in previously untreated patients with advanced/metastatic urothelial carcinoma (UC) who are ineligible for cisplatin-based chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Patients will receive gemcitabine 1200 mg/m2 intravenously on day 1 and day 8 and. Patients will receive 6 cycles of combination therapy (gemcitabine and pazopanib) unless disease progression or unacceptable toxicity occurs. Patients that achieve stable disease, a partial response, or a complete response after completion of 6 cycles, and who are not candidates for consolidation surgery, will be eligible to continue pazopanib monotherapy at the same dose and schedule until disease progression for a maximum of 18 additional cycles.</description>
    <arm_group_label>Gemcitabine and Pazopanib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pazopanib</intervention_name>
    <description>pazopanib 800 mg orally daily day 1 through day 21 (1 cycle = 21 days) Patients will receive 6 cycles of combination therapy (gemcitabine and pazopanib) unless disease progression or unacceptable toxicity occurs. Patients that achieve stable disease, a partial response, or a complete response after completion of 6 cycles, and who are not candidates for consolidation surgery, will be eligible to continue pazopanib monotherapy at the same dose and schedule until disease progression for a maximum of 18 additional cycles.</description>
    <arm_group_label>Gemcitabine and Pazopanib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Histologically confirmed diagnosis of urothelial carcinoma of the bladder, urethra,&#xD;
             ureter, or renal pelvis by MSKCC pathology review&#xD;
&#xD;
          -  Measurable disease as determined by RECIST v1.1 on initial pretreatment staging CT&#xD;
             scan of the chest, abdomen, and pelvis (or MRI if clinically appropriate). (Note: A&#xD;
             chest x-ray may be performed as an alternative to a CT scan of the chest.)&#xD;
&#xD;
          -  Ineligible for cisplatin based on one or more of the following:&#xD;
&#xD;
               -  Calculated creatinine clearance of &lt; 60 mL/min (but ≥ 30 mL/min)&#xD;
&#xD;
               -  Karnofsky Performance Status (KPS) 60-70% (ECOG PS 2)&#xD;
&#xD;
               -  Grade 2 ≥ hearing loss&#xD;
&#xD;
               -  Grade 2 ≥ peripheral neuropathy&#xD;
&#xD;
          -  Karnofsky Performance Status ≥ 60%&#xD;
&#xD;
          -  10 unstained slides or paraffin embedded tissue block obtained from pretreatment tumor&#xD;
             specimens for immunohistochemistry. (Note: One paraffin block or 10 freshly-prepared&#xD;
             unstained slides from the most representative single paraffin embedded tumor tissue&#xD;
             block should be submitted. Slides from the primary tumor are preferred. If both the&#xD;
             primary and metastatic tumor blocks are available, 10 slides from each of the sites&#xD;
             should be submitted. If tissue from the primary tumor is not available, a paraffin&#xD;
             block or unstained slides from a metastatic site are acceptable. Fine needle aspirates&#xD;
             (FNAs) have insufficient tumor tissue and are not permitted.)&#xD;
&#xD;
          -  Adequate organ system function as defined:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥1.5 X 109/L&#xD;
&#xD;
               -  Hemoglobin ≥9 g/dL (5.6 mmol/L) (Note: Subjects may not have had a transfusion&#xD;
                  within 7 days of screening assessment.)&#xD;
&#xD;
               -  Platelets ≥100 X 109/L&#xD;
&#xD;
               -  Prothrombin time (PT) or international normalized ratio (INR) ≤1.2 X ULN (Note:&#xD;
                  Subjects receiving anticoagulant therapy are eligible if their INR is stable and&#xD;
                  within the recommended range for the desired level of anticoagulation.)&#xD;
&#xD;
               -  Activated partial thromboplastin time (aPTT) ≤1.2 X ULN&#xD;
&#xD;
               -  Total bilirubin ≤1.5 X ULN&#xD;
&#xD;
               -  Alanine amino transferase (ALT) and Aspartate aminotransferase (AST)&#xD;
&#xD;
                  ≤2.5 X ULN (Note: Concomitant elevations in bilirubin and AST/ALT above 1.0 x ULN&#xD;
                  (upper limit of normal) are not permitted.)&#xD;
&#xD;
               -  Calculated creatinine clearance (ClCR) ≥30 mL/min using the CKD-EPI equation:&#xD;
                  eGFR = 141 x min(Scr/k, 1)a x max(Scr/k, 1)-1.209 x 0.993 Age x 1.018 [if female]&#xD;
                  x 1.159 [if black] Scr is serum creatinine, k is 0.7 for females and 0.9 for&#xD;
                  males, a is - 0.329 for females and -0.411 for males, min indicates the minimum&#xD;
                  of Scr/k or 1, and max indicates the maximum of Scr/k or 1&#xD;
&#xD;
               -  Urine Protein to Creatinine Ratio (UPC)d &lt;1 (Note: If UPC ≥1, then a 24- hour&#xD;
                  urine protein must be assessed. Subjects must have a 24-hour urine protein value&#xD;
                  &lt;1 g to be eligible.)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with systemic chemotherapy (prior intravesical therapy is permitted)&#xD;
&#xD;
          -  Prior malignancy (Note: Subjects who have had another malignancy and have been&#xD;
             disease-free for 5 years subjects with a history of completely resected&#xD;
             non-melanomatous skin carcinoma, subjects with successfully treated in situ carcinoma,&#xD;
             or subjects who have had adenocarcinoma of the prostate that has been definitively&#xD;
             treated with a post-treatment PSA that is non-detectable are eligible.)&#xD;
&#xD;
          -  History or clinical evidence of central nervous system (CNS) metastases or&#xD;
             leptomeningeal carcinomatosis, except for individuals who have previously-treated CNS&#xD;
             metastases, are asymptomatic, and have had no requirement for steroids or anti-seizure&#xD;
             medication for 6 months prior to first dose of study drug. Screening with CNS imaging&#xD;
             studies (computed tomography [CT] or magnetic resonance imaging [MRI]) is required&#xD;
             only if clinically indicated or if the subject has a history of CNS metastases.&#xD;
&#xD;
          -  Clinically significant gastrointestinal abnormalities that may increase the risk for&#xD;
             gastrointestinal bleeding including, but not limited to:&#xD;
&#xD;
               -  Active peptic ulcer disease&#xD;
&#xD;
               -  Known intraluminal metastatic lesion/s with risk of bleeding&#xD;
&#xD;
               -  Inflammatory bowel disease (e.g. ulcerative colitis, Crohn's disease), or other&#xD;
                  gastrointestinal conditions with increased risk of perforation&#xD;
&#xD;
               -  History of abdominal fistula, gastrointestinal perforation, or intra-abdominal&#xD;
                  abscess within 28 days prior to beginning study treatment Clinically significant&#xD;
                  gastrointestinal abnormalities that may affect absorption of investigational&#xD;
                  product including, but not limited to:&#xD;
&#xD;
               -  Malabsorption syndrome&#xD;
&#xD;
               -  Major resection of the stomach or small bowel&#xD;
&#xD;
          -  Active liver disease such as cirrhosis, chronic active hepatitis, or chronic&#xD;
             persistent hepatitis&#xD;
&#xD;
          -  Presence of uncontrolled infection Corrected QT interval (QTc) &gt; 480 msecs using&#xD;
             Bazett's formula&#xD;
&#xD;
             o If QTc interval is &gt; 480 msecs, then 2 additional ECGs should be obtained over a&#xD;
             brief period of time (e.g., within approximately 15-20 minutes) to confirm the&#xD;
             abnormality. The average QTc interval will be determined from the 3 ECG tracings by&#xD;
             manual evaluation and will be used to determine if the subject will be excluded from&#xD;
             the study. If the average QTc interval is &gt;480 msec, then the subject is not eligible&#xD;
             to participate in the study Previous history of QTc prolongation as a result of other&#xD;
             medication that required discontinuation of that medication&#xD;
&#xD;
          -  Congenital long QT syndrome or 1st degree relative with unexplained sudden death under&#xD;
             40 years of age&#xD;
&#xD;
          -  Use of any concomitant medication (during treatment with pazopanib or within 14 days&#xD;
             of starting treatment) that are high risk for QTc prolongation or may induce Torsades&#xD;
             de Pointes.&#xD;
&#xD;
          -  History of any one or more of the following cardiovascular conditions within the past&#xD;
             6 months:&#xD;
&#xD;
               -  Cardiac angioplasty or stenting&#xD;
&#xD;
               -  Myocardial infarction Unstable angina&#xD;
&#xD;
               -  Coronary artery bypass graft surgery&#xD;
&#xD;
               -  Symptomatic peripheral vascular disease&#xD;
&#xD;
               -  Class III or IV congestive heart failure, as defined by the New York Heart&#xD;
                  Association (NYHA)&#xD;
&#xD;
          -  Poorly controlled hypertension [defined as systolic blood pressure (SBP) of ≥140 mmHg&#xD;
             or diastolic blood pressure (DBP) of ≥ 90mmHg] (Note: Initiation or adjustment of&#xD;
             antihypertensive medication(s) is permitted prior to study entry. At least 24 hours&#xD;
             after initiation or adjustment of antihypertensive medication (s), BP must be&#xD;
             re-assessed on two occasions that are separated by a minimum of 1 hour; on each of&#xD;
             these occasions, the mean (of 3 readings) SBP / DBP values from each BP assessment&#xD;
             must be &lt;140/90 mmHg in order for a subject to be eligible for the study.)&#xD;
&#xD;
          -  History of cerebrovascular accident including transient ischemic attack (TIA),&#xD;
             pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months.&#xD;
             (Note: Subjects with recent DVT who have been treated with therapeutic&#xD;
             anti-coagulating agents for at least 6 weeks are eligible.)&#xD;
&#xD;
          -  Prior major surgery or trauma within 28 days prior to first dose of study drug and/or&#xD;
             presence of any non-healing wound, fracture, or ulcer (procedures such as catheter&#xD;
             placement not considered to be major).&#xD;
&#xD;
          -  Evidence of active bleeding or bleeding diathesis. Known endobronchial lesions and/or&#xD;
             lesions infiltrating major pulmonary vessels&#xD;
&#xD;
          -  Hemoptysis in excess of 2.5 mL (or one half teaspoon) within 8 weeks of first dose of&#xD;
             study drug.&#xD;
&#xD;
          -  Any serious and/or unstable pre-existing medical, psychiatric, or other condition that&#xD;
             could interfere with subject's safety, provision of informed consent, or compliance to&#xD;
             study procedures.&#xD;
&#xD;
          -  Unable or unwilling to discontinue use of prohibited medications listed in&#xD;
             (Concomitant Therapy) for at least 14 days or five half-lives of a drug (whichever is&#xD;
             longer) prior to the first dose of study drug and for the duration of the study&#xD;
&#xD;
          -  Treatment with any of the following anti-cancer therapies:&#xD;
&#xD;
               -  Radiation therapy, surgery or tumor embolization within 14 days prior to the&#xD;
                  first dose of pazopanib OR&#xD;
&#xD;
               -  Immunotherapy, biologic therapy, investigational therapy or hormonal therapy&#xD;
                  within 14 days or five half-lives of a drug (whichever is longer) prior to the&#xD;
                  first dose of pazopanib Administration of any non-oncologic investigational drug&#xD;
                  within 30 days or 5 half lives whichever is longer prior to receiving the first&#xD;
                  dose of study treatment&#xD;
&#xD;
          -  Any ongoing toxicity from prior anti-cancer therapy that is &gt;Grade 1 and/or that is&#xD;
             progressing in severity&#xD;
&#xD;
          -  Women who are pregnant or breast feeding (Female subjects who are lactating should&#xD;
             discontinue nursing prior to the first dose of study drug and should refrain from&#xD;
             nursing throughout the treatment period and for 14 days following the last dose of&#xD;
             study drug.)&#xD;
&#xD;
          -  Adults of child-bearing potential not employing an effective method of birth control&#xD;
             for two weeks prior to study start and 21 days after the last dose. All women of&#xD;
             child-bearing potential must have a negative serum pregnancy test. Women of&#xD;
             child-bearing potential are defined as sexually mature women who have not undergone a&#xD;
             hysterectomy, bilateral oophorectomy (ovariectomy), or bilateral tubal ligation OR&#xD;
             have not experienced total cessation of menses for ≥ 1 year and are older than 45&#xD;
             years in age, In questionable cases, the patient must have a follicle stimulating&#xD;
             hormone (FSH) value &gt;40 mIU/mL and an estradiol value &lt; 40pg/mL (&lt;140 pmol/L).&#xD;
             Effective methods of birth control are defined in section 9.9 (Contraception&#xD;
             Requirements).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dean Bajorin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Cancer Center</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center @ Suffolk</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center at Mercy Medical Center</name>
      <address>
        <city>Rockville Centre</city>
        <state>New York</state>
        <zip>11570</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center at Phelps Memorial Hospital Center</name>
      <address>
        <city>Sleepy Hollow</city>
        <state>New York</state>
        <zip>10591</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>June 15, 2012</study_first_submitted>
  <study_first_submitted_qc>June 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2012</study_first_posted>
  <results_first_submitted>January 23, 2017</results_first_submitted>
  <results_first_submitted_qc>July 24, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 22, 2017</results_first_posted>
  <last_update_submitted>July 24, 2017</last_update_submitted>
  <last_update_submitted_qc>July 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>URETER</keyword>
  <keyword>URINARY BLADDER</keyword>
  <keyword>renal pelvis</keyword>
  <keyword>GEMCITABINE</keyword>
  <keyword>GW786034 (PAZOPANIB)</keyword>
  <keyword>11-191</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Protocol Open to Accrual 06/14/2012 Protocol Closed to Accrual 02/05/2014 Primary Completion Date 02/03/2016 Recruitment Location is the medical clinic</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Gemcitabine and Pazopanib</title>
          <description>Chemotherapy naïve participants with advanced/metastatic urothelial carcinoma ineligible for Cisplatin-based chemotherapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Gemcitabine and Pazopanib</title>
          <description>This is a phase II trial of gemcitabine and pazopanib in previously untreated patients with advanced/metastatic urothelial carcinoma (UC) who are ineligible for cisplatin-based chemotherapy.&#xD;
Gemcitabine and Pazopanib: Patients will receive gemcitabine 1200 mg/m2 intravenously on day 1 and day 8 and pazopanib 800 mg orally daily day 1 through day 21 (1 cycle = 21 days). Patients will receive 6 cycles of combination therapy (gemcitabine and pazopanib) unless disease progression or unacceptable toxicity occurs. Patients that achieve stable disease, a partial response, or a complete response after completion of 6 cycles, and who are not candidates for consolidation surgery, will be eligible to continue pazopanib monotherapy at the same dose and schedule until disease progression for a maximum of 18 additional cycles.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.5" lower_limit="60" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival (PFS)</title>
        <description>Progression Free Survival will be calculated from the start of treatment until progressive disease or death. Patients who die before documented progression will be considered failures at their time of death. If the patient did not progress or die, the patient will be censored on the date of last follow-up. Response and progression will be evaluated in this study using the international criteria by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 Measurable lesions: lesions that can be accurately measured in at least one dimension with longest diameter ≥ 10 mm by clinical exam or with spiral CT scan or MRI (no less than double the slice thickness and a minimum of 10mm). Malignant lymph nodes must be 15 mm in the short axis when assessed by spiral CT scan to be considered measurable. Non-measurable lesions: all other lesions (or sites of disease) including small lesions (longest diameter &lt; 20 mm with conventional techniques or &lt; 10 mm u</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gemcitabine and Pazopanib</title>
            <description>This is a phase II trial of gemcitabine and pazopanib in previously untreated patients with advanced/metastatic urothelial carcinoma (UC) who are ineligible for cisplatin-based chemotherapy.&#xD;
Gemcitabine and Pazopanib: Patients will receive gemcitabine 1200 mg/m2 intravenously on day 1 and day 8 and pazopanib 800 mg orally daily day 1 through day 21 (1 cycle = 21 days). Patients will receive 6 cycles of combination therapy (gemcitabine and pazopanib) unless disease progression or unacceptable toxicity occurs. Patients that achieve stable disease, a partial response, or a complete response after completion of 6 cycles, and who are not candidates for consolidation surgery, will be eligible to continue pazopanib monotherapy at the same dose and schedule until disease progression for a maximum of 18 additional cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS)</title>
          <description>Progression Free Survival will be calculated from the start of treatment until progressive disease or death. Patients who die before documented progression will be considered failures at their time of death. If the patient did not progress or die, the patient will be censored on the date of last follow-up. Response and progression will be evaluated in this study using the international criteria by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 Measurable lesions: lesions that can be accurately measured in at least one dimension with longest diameter ≥ 10 mm by clinical exam or with spiral CT scan or MRI (no less than double the slice thickness and a minimum of 10mm). Malignant lymph nodes must be 15 mm in the short axis when assessed by spiral CT scan to be considered measurable. Non-measurable lesions: all other lesions (or sites of disease) including small lesions (longest diameter &lt; 20 mm with conventional techniques or &lt; 10 mm u</description>
          <units>days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>0.8 months to 6.3 months</time_frame>
      <desc>Adverse event data were collected for the duration of treatment. For Patient 001 this was 0.8 months. For Patient 002 this was 6.3 months.</desc>
      <group_list>
        <group group_id="E1">
          <title>Gemcitabine and Pazopanib</title>
          <description>This is a phase II trial of gemcitabine and pazopanib in previously untreated patients with advanced/metastatic urothelial carcinoma (UC) who are ineligible for cisplatin-based chemotherapy.&#xD;
Gemcitabine and Pazopanib: Patients will receive gemcitabine 1200 mg/m2 intravenously on day 1 and day 8 and pazopanib 800 mg orally daily day 1 through day 21 (1 cycle = 21 days). Patients will receive 6 cycles of combination therapy (gemcitabine and pazopanib) unless disease progression or unacceptable toxicity occurs. Patients that achieve stable disease, a partial response, or a complete response after completion of 6 cycles, and who are not candidates for consolidation surgery, will be eligible to continue pazopanib monotherapy at the same dose and schedule until disease progression for a maximum of 18 additional cycles.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated ALT with concomitant elevation in Bilirubin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders, other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated ALT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Elevated Alkaline Phosphatase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Elevated AST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Blood Bilrubin Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>INR increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Dean Bajorin</name_or_title>
      <organization>Memorial Sloan Kettering Cancer Center</organization>
      <phone>646-422-4333</phone>
      <email>bajorind@mskcc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

